tregalizumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
tregalizumab

GtoPdb Ligand ID: 9864

Synonyms: BT-061 | hB-F5

Compound class: Antibody

Comment: Tregalizumab (BT-061) is an anti-CD4 monoclonal antibody that was developed by Biotest Ag as a potential anti-rheumatoid arthritis therapy [4].

Summary
Biological activity
Clinical data
References
Immunopharmacology

Immunopharmacology Comments
Tregalizumab was designed to selectively activate Treg cells and boost their function to mediate an increase in their immunosuppressive activity [1-2].

Immunopharmacology Comments

Tregalizumab was designed to selectively activate Treg cells and boost their function to mediate an increase in their immunosuppressive activity [1-2].

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Rheumatoid arthritis	Disease Ontology: DOID:7148 OMIM: 180300	Tregalizumab failed to show clinical efficacy in Phase 2 trial (NCT01999192), and development was discontinued.	3